Rademikibart (CBP-201) is a humanised monoclonal antibody targeting IL-4Ralpha (KD = 20.7 pM) that does not interact with IL-4Ralpha from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signalling pathways, TF-1 cell proliferation, and TARC production in PBMCs, making it useful for studying Th2-type inflammatory diseases.
Reinheit:
98.30%
CAS Nummer:
[2648260-80-2]
Target-Kategorie:
IL Receptor|||Interleukin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten